Back to search
Hepatitis b & Liver Dysfunction
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hepatitis b & Liver Dysfunction trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hepatitis b & Liver Dysfunction trials you may qualify forThe goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated…
Background Chronic hepatitis B (CHB) is a global health issue that affects a large number of patients. There is currently controversy regarding the treatment st…
This multicenter retrospective study aims to study the association between the presence of MAFLD and change in liver stiffness over time in untreated and treate…
Chronic hepatitis B (CHB) infection remains an important public health with more than 240 million people chronically infected despite the existence of an effect…
1. Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target patients (patients with chronic viral hepatitis b with liver fibrosis) and…
The investigators aim at describing changes in renal glomerular and tubular function with after the switch from TDF to TAF in HIV/HBV-coinfected patients with m…
Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure. The optim…
Nucleotide anti-viral analogues, including adefovir and TDF, have demonstrated kidney toxicity in HIV/HBV co-infected patients and HBV mono-infected European pa…
The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.